Outcomes associated with pharmacologic treatments in Parkinson's disease: a review of recent literature.
Parkinson's disease (PD) affects nearly 1 million Americans with a mean onset age of 60 years. Its progressive, neurodegenerative nature, causing motor complications and affecting mood, has a considerable impact on a patient's health-related quality of life. Pharmacologic therapies are the most widely utilized treatment. The broad range of drugs for treating PD warrants an assessment of each medication's health-related outcomes, which includes consideration of clinical, economic and patient-centered outcomes. This review seeks to explore the outcomes associated with drugs frequently appearing in the literature of the past 5 years and to comment on the direction of pharmacologic research and management of PD pharmacotherapy in the future.
Iaconi
Ala I
AI
Ohio State University College of Pharmacy, 500 W. 12th Avenue, Columbus, OH 43210, USA.
Zimmerman
Marliese A
MA
Kulkarni
Amit S
AS
Balkrishnan
Rajesh
R
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology* / Q000523:psychology; D011788:Quality of Life / Q000523:psychology; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000639:trends; D016896:Treatment Outcome
D000978:Antiparkinson Agents